newsfilter
← Latest News
GlobeNewswire·

Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting

LKFT
  • Lakefront Biotherapeutics announced the acceptance of a poster presentation on gamgertamig data at the 2026 American Society of Hematology Annual Meeting in New Orleans.
  • Preliminary Phase 1b data suggest the potential to retain remission after B cell reconstitution without background therapy, consistent with an "immune reset" for autoimmune cytopenias.
  • The poster details initial global clinical experience with gamgertamig in 33 patients, comprising 22 with immune thrombocytopenia (ITP) and 11 with autoimmune hemolytic anemia (AIHA).
  • Dosing involved a short course of subcutaneous administration over a maximum of three weeks across three dose cohorts.
  • In the ITP cohort, 90% of response-evaluable patients achieved a response, with 94% of responders achieving normalization of platelet counts.
  • In the AIHA cohort, all response-evaluable patients in the mid and high dose cohorts achieved a response defined as a hemoglobin increase of at least 2 g/dL.
  • Median time to response was 11 days for ITP patients and 22 days for AIHA patients.
  • Durability of response showed 83% of ITP responders and 89% of AIHA responders maintaining ongoing responses at the most recent follow-up.
  • Safety data indicated Grade 1 cytokine release syndrome in 18% of patients, with no Grade 2 or higher CRS, neurotoxicity, or severe infections observed.
  • Lakefront will host an investor conference call on Monday, December 14, at 8:00 AM ET to discuss the data.
  • Gamgertamig is an investigational BCMAxCD3 bispecific T cell engager granted Orphan Drug and Fast Track Designations by the U.S. FDA.
  • The company expects gamgertamig to enter registrational studies in 2027.